ECOG-ACRIN Cancer Research Group
@eaonc.bsky.social
Biomarker-driven medical research involving adults who have or are at risk of developing cancer
Only about 7% of US patients with #cancer take part in #ClinicalTrials, and distance is a major barrier. Cooperative groups supported by The NCI's Community Oncology Research Program help bring trials to community sites closer to home. Learn more: bit.ly/3TqHCVU
Bringing Oncology Trials Closer to Home: Are We Rising to the Challenge?
A significant barrier to increasing oncology trial participation is a physical mismatch between sites with appropriate trial options and the locations where patients live and seek care. In order to re...
bit.ly
October 1, 2026 at 7:26 PM
Only about 7% of US patients with #cancer take part in #ClinicalTrials, and distance is a major barrier. Cooperative groups supported by The NCI's Community Oncology Research Program help bring trials to community sites closer to home. Learn more: bit.ly/3TqHCVU
Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. https://bit.ly/ea8231-study
October 1, 2026 at 3:00 PM
Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. https://bit.ly/ea8231-study
Consistent, evidence-based funding has helped deliver major advances in #cancer treatment. @acscan.bsky.social shares its perspective on a reported change to #NIH grantmaking and what it could mean for research: bit.ly/4xPN16S
ACS CAN Warns Political Interference Could Threaten Cancer Research
The American Cancer Society Cancer Action Network (ACS CAN) today expressed deep concern following media reports of a new planned executive order placing greater political control over research grant ...
bit.ly
September 29, 2026 at 3:41 PM
Consistent, evidence-based funding has helped deliver major advances in #cancer treatment. @acscan.bsky.social shares its perspective on a reported change to #NIH grantmaking and what it could mean for research: bit.ly/4xPN16S
Reposted by ECOG-ACRIN Cancer Research Group
Thank you for sharing our powerful five-minute video @eaonc.bsky.social! I really helps frame clinical trials from the participant's point of view.
Powerful video by our colleagues at @alliance-org.bsky.social! #Cancer #ClinicalTrial participation can save lives.
Clinical trials help advance cancer research and care—but they depend on people willing to participate. Our new film shares one participant’s story and the vital role volunteers play in improving cancer treatment. You can view the five-minute #RewritingCancer film here: https://bit.ly/Alliance-Video
September 21, 2026 at 3:15 AM
Thank you for sharing our powerful five-minute video @eaonc.bsky.social! I really helps frame clinical trials from the participant's point of view.
The #BreastCancer study EA1242/RxFINE-Low is testing whether hormone therapy plus ribociclib, without chemotherapy, is as effective as standard treatment that includes chemotherapy. Learn more: https://bit.ly/ea1242-study
September 29, 2026 at 3:00 PM
The #BreastCancer study EA1242/RxFINE-Low is testing whether hormone therapy plus ribociclib, without chemotherapy, is as effective as standard treatment that includes chemotherapy. Learn more: https://bit.ly/ea1242-study
#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
September 29, 2026 at 2:00 PM
#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
#ClinicalTrial EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: https://bit.ly/EA7211
September 28, 2026 at 4:00 PM
#ClinicalTrial EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: https://bit.ly/EA7211
#FindingsFriday: New research from 9 ECOG-ACRIN Cancer Research Group trials found most patients who smoked before their #cancer diagnosis kept smoking—during and after treatment. #SmokingCessation support needs to be built into cancer care, not left to chance. Learn more: https://bit.ly/4dvJZxj
September 25, 2026 at 6:10 PM
#FindingsFriday: New research from 9 ECOG-ACRIN Cancer Research Group trials found most patients who smoked before their #cancer diagnosis kept smoking—during and after treatment. #SmokingCessation support needs to be built into cancer care, not left to chance. Learn more: https://bit.ly/4dvJZxj
ICYMI, more than a decade after TAILORx changed #BreastCancer care, its biorepository is yielding new insights: researchers used #AI to review archived pathology slides from 4,000+ trial participants, developing a more accurate recurrence-risk model. More: https://bit.ly/4cY42EB
A new AI-powered test offers more accurate prediction of breast cancer recurrence risk
Learn how ECOG-ACRIN is using an innovative artificial intelligence (AI) model to create more accurate recurrence risk predictions in patients with early-stage breast cancer.
bit.ly
September 24, 2026 at 8:00 PM
ICYMI, more than a decade after TAILORx changed #BreastCancer care, its biorepository is yielding new insights: researchers used #AI to review archived pathology slides from 4,000+ trial participants, developing a more accurate recurrence-risk model. More: https://bit.ly/4cY42EB
EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with advanced urothelial cancer. The trial aims to improve treatment options & guide further research. ➡️ https://bit.ly/ea8231-study
September 24, 2026 at 3:00 PM
EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with advanced urothelial cancer. The trial aims to improve treatment options & guide further research. ➡️ https://bit.ly/ea8231-study
Decades of federal investment in #CancerResearch have saved millions of lives. American Association for Cancer Research (AACR)'s Cancer Progress Report asks Congress to sustain NIH/NCI funding & protect grants from interference—because progress against #cancer depends on it. https://bit.ly/4xC3bRk
September 22, 2026 at 8:00 PM
Decades of federal investment in #CancerResearch have saved millions of lives. American Association for Cancer Research (AACR)'s Cancer Progress Report asks Congress to sustain NIH/NCI funding & protect grants from interference—because progress against #cancer depends on it. https://bit.ly/4xC3bRk
Do you have #BreastCancer that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: https://bit.ly/ea1242-study
September 22, 2026 at 3:00 PM
Do you have #BreastCancer that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: https://bit.ly/ea1242-study
Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://bit.ly/ea5221-achieve
September 22, 2026 at 2:00 PM
Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://bit.ly/ea5221-achieve
Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona aims to find out. More: https://bit.ly/EA7211 cc: European Organisation for Research and Treatment of Cancer
September 21, 2026 at 4:00 PM
Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona aims to find out. More: https://bit.ly/EA7211 cc: European Organisation for Research and Treatment of Cancer
#FindingsFriday: New results from CompassHER2 pCR help identify factors associated w/ pathologic complete response in HER2+ #BreastCancer. Research like this moves us closer to more personalized treatment strategies. More in JCO Journals: https://bit.ly/4hqJjM3 #ClinicalTrials
September 18, 2026 at 2:00 PM
#FindingsFriday: New results from CompassHER2 pCR help identify factors associated w/ pathologic complete response in HER2+ #BreastCancer. Research like this moves us closer to more personalized treatment strategies. More in JCO Journals: https://bit.ly/4hqJjM3 #ClinicalTrials
#CancerResearch advances through collaboration. In our latest Institution Spotlight, Dr. Joseph Sparano shares how the Mount Sinai Tisch Cancer Center is contributing to NCI-funded clinical research, incl. the ongoing EA1241 trial, while helping cultivate future leaders. More: https://bit.ly/4xt4ty2
Institution Spotlight: Mount Sinai Tisch Cancer Center
Showcasing the center's commitment to training oncology researchers and improving patient outcomes through impactful cancer clinical trials
bit.ly
September 17, 2026 at 7:00 PM
#CancerResearch advances through collaboration. In our latest Institution Spotlight, Dr. Joseph Sparano shares how the Mount Sinai Tisch Cancer Center is contributing to NCI-funded clinical research, incl. the ongoing EA1241 trial, while helping cultivate future leaders. More: https://bit.ly/4xt4ty2
Clinical trial EA8231, led by Monika Joshi, MD and Petros Grivas, MD, PhD, is a phase 3 randomized study exploring a new treatment approach for pts with treatment-refractory, locally-advanced or metastatic urothelial cancer. More information here: https://bit.ly/ea8231-study
September 17, 2026 at 3:00 PM
Clinical trial EA8231, led by Monika Joshi, MD and Petros Grivas, MD, PhD, is a phase 3 randomized study exploring a new treatment approach for pts with treatment-refractory, locally-advanced or metastatic urothelial cancer. More information here: https://bit.ly/ea8231-study
Powerful video by our colleagues at @alliance-org.bsky.social! #Cancer #ClinicalTrial participation can save lives.
Clinical trials help advance cancer research and care—but they depend on people willing to participate. Our new film shares one participant’s story and the vital role volunteers play in improving cancer treatment. You can view the five-minute #RewritingCancer film here: https://bit.ly/Alliance-Video
September 15, 2026 at 7:27 PM
Powerful video by our colleagues at @alliance-org.bsky.social! #Cancer #ClinicalTrial participation can save lives.
Clinical trial EA1242/RxFINE-Low, led by Dr. Nancy Chan of Perlmutter Cancer Center at NYU Langone Health, is testing whether hormone therapy plus ribociclib is as effective as chemotherapy followed by hormone therapy plus ribociclib in patients with #BreastCancer. More: https://bit.ly/ea1242-study
September 15, 2026 at 3:00 PM
Clinical trial EA1242/RxFINE-Low, led by Dr. Nancy Chan of Perlmutter Cancer Center at NYU Langone Health, is testing whether hormone therapy plus ribociclib is as effective as chemotherapy followed by hormone therapy plus ribociclib in patients with #BreastCancer. More: https://bit.ly/ea1242-study
The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
September 15, 2026 at 2:00 PM
The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
#CancerResearch progress is not guaranteed. As the American Society of Clinical Oncology's Save Research campaign highlights, continued federal investment is critical to supporting researchers, fueling innovation, & advancing #ClinicalTrials. More: https://bit.ly/3V9APjK #SaveResearchStopCancer
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline.
bit.ly
September 15, 2026 at 1:00 PM
#CancerResearch progress is not guaranteed. As the American Society of Clinical Oncology's Save Research campaign highlights, continued federal investment is critical to supporting researchers, fueling innovation, & advancing #ClinicalTrials. More: https://bit.ly/3V9APjK #SaveResearchStopCancer
In #ClinicalTrial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery alone for patients with high-risk retroperitoneal #sarcoma. More info: https://bit.ly/EA7211
September 14, 2026 at 4:00 PM
In #ClinicalTrial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery alone for patients with high-risk retroperitoneal #sarcoma. More info: https://bit.ly/EA7211
Encouraging news: #cancer survival rates among adolescents & young adults (#AYAs) continue to improve. Study authors: "Much of this progress can be attributed to national efforts led by NCI-funded cooperative groups to focus on AYA oncology." bit.ly/3TfrypP #AYACancer
Young Adult Cancer Survival Rates Accelerate
Researchers have analyzed annual survival data between AYA patients aged 15-39 years and patients in younger and older age groups between 1975 and 2017.
bit.ly
September 10, 2026 at 7:26 PM
Encouraging news: #cancer survival rates among adolescents & young adults (#AYAs) continue to improve. Study authors: "Much of this progress can be attributed to national efforts led by NCI-funded cooperative groups to focus on AYA oncology." bit.ly/3TfrypP #AYACancer
#Cancer #ClinicalTrials depend on a strong & stable research infrastructure. Consistent federal funding helps support the #science that brings innovative treatments to patients & advances cancer care. @americancancersoc.bsky.social is urging Congress to pass a full-year budget: bit.ly/4yr6sn9
ACS CAN Calls on Congress to Pass Full-Year Budget; Preserve Stability in Federal Research Funding
Today, the House passed a continuing resolution (CR) to fund the federal government through mid-December.
bit.ly
September 9, 2026 at 8:19 PM
#Cancer #ClinicalTrials depend on a strong & stable research infrastructure. Consistent federal funding helps support the #science that brings innovative treatments to patients & advances cancer care. @americancancersoc.bsky.social is urging Congress to pass a full-year budget: bit.ly/4yr6sn9
Federal investment in #cancer #ClinicalTrials matters. A recent study found that federally funded trials are more likely to examine rare & pediatric cancers, prevention strategies, supportive care, & ways to reduce treatment burden. More via @theaacr.bsky.social's blog: bit.ly/4zS7fzm
Unboxing Cancer News, August 2026: Fishy Cancer, Federal- vs. Industry-funded Trials, and More
The August 2026 edition of “Unboxing Cancer News” highlights a transmissible cancer, federal- vs. industry-funded clinical trials, and more.
bit.ly
September 2, 2026 at 4:14 PM
Federal investment in #cancer #ClinicalTrials matters. A recent study found that federally funded trials are more likely to examine rare & pediatric cancers, prevention strategies, supportive care, & ways to reduce treatment burden. More via @theaacr.bsky.social's blog: bit.ly/4zS7fzm